Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 22 entries
Sorted by: Best Match Show Resources per page
Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk.

Frontiers in endocrinology

Morimont L, Haguet H, Dogné JM, Gaspard U, Douxfils J.
PMID: 34956081
Front Endocrinol (Lausanne). 2021 Dec 09;12:769187. doi: 10.3389/fendo.2021.769187. eCollection 2021.

Many factors must be considered and discussed with women when initiating a contraceptive method and the risk of venous thromboembolism (VTE) is one of them. In this review, we discuss the numerous strategies that have been implemented to reduce...

Cite
Morimont L, Haguet H, Dogné JM, et al. Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk. Front Endocrinol (Lausanne). 2021;12:769187doi: 10.3389/fendo.2021.769187.
Morimont, L., Haguet, H., Dogné, J. M., Gaspard, U., & Douxfils, J. (2021). Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk. Frontiers in endocrinology, 12769187. https://doi.org/10.3389/fendo.2021.769187
Morimont, Laure, et al. "Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk." Frontiers in endocrinology vol. 12 (2021): 769187. doi: https://doi.org/10.3389/fendo.2021.769187
Morimont L, Haguet H, Dogné JM, Gaspard U, Douxfils J. Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk. Front Endocrinol (Lausanne). 2021 Dec 09;12:769187. doi: 10.3389/fendo.2021.769187. eCollection 2021. PMID: 34956081; PMCID: PMC8697849.
Copy Download .nbib Format: NLM
Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk.

Frontiers in endocrinology

Morimont L, Haguet H, Dogné JM, Gaspard U, Douxfils J.
PMID: 34956081
Front Endocrinol (Lausanne). 2021 Dec 09;12:769187. doi: 10.3389/fendo.2021.769187. eCollection 2021.

Many factors must be considered and discussed with women when initiating a contraceptive method and the risk of venous thromboembolism (VTE) is one of them. In this review, we discuss the numerous strategies that have been implemented to reduce...

Cite
Morimont L, Haguet H, Dogné JM, et al. Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk. Front Endocrinol (Lausanne). 2021;12:769187doi: 10.3389/fendo.2021.769187.
Morimont, L., Haguet, H., Dogné, J. M., Gaspard, U., & Douxfils, J. (2021). Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk. Frontiers in endocrinology, 12769187. https://doi.org/10.3389/fendo.2021.769187
Morimont, Laure, et al. "Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk." Frontiers in endocrinology vol. 12 (2021): 769187. doi: https://doi.org/10.3389/fendo.2021.769187
Morimont L, Haguet H, Dogné JM, Gaspard U, Douxfils J. Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk. Front Endocrinol (Lausanne). 2021 Dec 09;12:769187. doi: 10.3389/fendo.2021.769187. eCollection 2021. PMID: 34956081; PMCID: PMC8697849.
Copy Download .nbib Format: NLM
Oral contraceptives: an update.

Drugs of today (Barcelona, Spain : 1998)

Burkman RT.
PMID: 12973377
Drugs Today (Barc). 1999 Nov;35(11):857-66. doi: 10.1358/dot.1999.35.11.562559.

Oral contraceptives are used by large numbers of reproductive-aged women across the world. Recent data examining cardiovascular risk indicates a persistent risk for venous thromboembolism among all oral contraceptive users. This risk is enhanced by the presence of hemostatic...

Cite
Burkman RT. Oral contraceptives: an update. Drugs Today (Barc). 1999;35(11):857-66doi: 10.1358/dot.1999.35.11.562559.
Burkman, R. T. (1999). Oral contraceptives: an update. Drugs of today (Barcelona, Spain : 1998), 35(11), 857-66. https://doi.org/10.1358/dot.1999.35.11.562559
Burkman, R T. "Oral contraceptives: an update." Drugs of today (Barcelona, Spain : 1998) vol. 35,11 (1999): 857-66. doi: https://doi.org/10.1358/dot.1999.35.11.562559
Burkman RT. Oral contraceptives: an update. Drugs Today (Barc). 1999 Nov;35(11):857-66. doi: 10.1358/dot.1999.35.11.562559. PMID: 12973377.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 16258596
Methods Find Exp Clin Pharmacol. 2005 Sep;27(7):505-22.

Gateways to Clinical Trials are a guide to the most recent clinical trials in the current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005;27(7):505-22
Bayés, M., Rabasseda, X., & Prous, J. R. (2005). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 27(7), 505-22.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 27,7 (2005): 505-22.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Sep;27(7):505-22. PMID: 16258596.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X.
PMID: 18389098
Methods Find Exp Clin Pharmacol. 2008 Jan-Feb;30(1):67-99.

Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prouse Science Integrity, the drug...

Cite
Bayés M, Rabasseda X. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008;30(1):67-99
Bayés, M., & Rabasseda, X. (2008). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 30(1), 67-99.
Bayés, M, and Rabasseda, X. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 30,1 (2008): 67-99.
Bayés M, Rabasseda X. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Jan-Feb;30(1):67-99. PMID: 18389098.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 17344945
Methods Find Exp Clin Pharmacol. 2007 Jan-Feb;29(1):53-71.

Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007;29(1):53-71
Bayés, M., Rabasseda, X., & Prous, J. R. (2007). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 29(1), 53-71.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 29,1 (2007): 53-71.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Jan-Feb;29(1):53-71. PMID: 17344945.
Copy Download .nbib Format: NLM
Combining oral contraceptives with a natural nuclear factor-kappa B inhibitor for the treatment of endometriosis-related pain.

International journal of women's health

Maia H, Haddad C, Casoy J.
PMID: 24379702
Int J Womens Health. 2013 Dec 21;6:35-9. doi: 10.2147/IJWH.S55210. eCollection 2013.

Endometriosis is a chronic disease in which a persistent state of heightened inflammation is maintained by nuclear factor-kappa B (NF-κB) activation. The progestins present in oral contraceptives are potent inhibitors of NF-κB translocation to cell nuclei, while Pycnogenol® (Pinus...

Cite
Maia H, Haddad C, Casoy J. Combining oral contraceptives with a natural nuclear factor-kappa B inhibitor for the treatment of endometriosis-related pain. Int J Womens Health. 2013;6:35-9doi: 10.2147/IJWH.S55210.
Maia, H., Haddad, C., & Casoy, J. (2013). Combining oral contraceptives with a natural nuclear factor-kappa B inhibitor for the treatment of endometriosis-related pain. International journal of women's health, 635-9. https://doi.org/10.2147/IJWH.S55210
Maia, Hugo, et al. "Combining oral contraceptives with a natural nuclear factor-kappa B inhibitor for the treatment of endometriosis-related pain." International journal of women's health vol. 6 (2013): 35-9. doi: https://doi.org/10.2147/IJWH.S55210
Maia H, Haddad C, Casoy J. Combining oral contraceptives with a natural nuclear factor-kappa B inhibitor for the treatment of endometriosis-related pain. Int J Womens Health. 2013 Dec 21;6:35-9. doi: 10.2147/IJWH.S55210. eCollection 2013. PMID: 24379702; PMCID: PMC3873204.
Copy Download .nbib Format: NLM
The effect of pycnogenol on patients with dysmenorrhea using low-dose oral contraceptives.

International journal of women's health

Maia H, Haddad C, Casoy J.
PMID: 25525393
Int J Womens Health. 2014 Dec 11;6:1019-22. doi: 10.2147/IJWH.S75389. eCollection 2014.

OBJECTIVE: Menstrual symptoms such as dysmenorrhea usually occur during the hormone-free interval in oral contraceptive users. Progestin withdrawal activates NF-κB transcription factor, which upregulates both vascular endothelial growth factor (VEGF) and Cox-2 expression in the endometrium. The use of...

Cite
Maia H, Haddad C, Casoy J. The effect of pycnogenol on patients with dysmenorrhea using low-dose oral contraceptives. Int J Womens Health. 2014;6:1019-22doi: 10.2147/IJWH.S75389.
Maia, H., Haddad, C., & Casoy, J. (2014). The effect of pycnogenol on patients with dysmenorrhea using low-dose oral contraceptives. International journal of women's health, 61019-22. https://doi.org/10.2147/IJWH.S75389
Maia, Hugo, et al. "The effect of pycnogenol on patients with dysmenorrhea using low-dose oral contraceptives." International journal of women's health vol. 6 (2014): 1019-22. doi: https://doi.org/10.2147/IJWH.S75389
Maia H, Haddad C, Casoy J. The effect of pycnogenol on patients with dysmenorrhea using low-dose oral contraceptives. Int J Womens Health. 2014 Dec 11;6:1019-22. doi: 10.2147/IJWH.S75389. eCollection 2014. PMID: 25525393; PMCID: PMC4266261.
Copy Download .nbib Format: NLM
Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk.

Frontiers in endocrinology

Morimont L, Haguet H, Dogné JM, Gaspard U, Douxfils J.
PMID: 34956081
Front Endocrinol (Lausanne). 2021 Dec 09;12:769187. doi: 10.3389/fendo.2021.769187. eCollection 2021.

Many factors must be considered and discussed with women when initiating a contraceptive method and the risk of venous thromboembolism (VTE) is one of them. In this review, we discuss the numerous strategies that have been implemented to reduce...

Cite
Morimont L, Haguet H, Dogné JM, et al. Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk. Front Endocrinol (Lausanne). 2021;12:769187doi: 10.3389/fendo.2021.769187.
Morimont, L., Haguet, H., Dogné, J. M., Gaspard, U., & Douxfils, J. (2021). Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk. Frontiers in endocrinology, 12769187. https://doi.org/10.3389/fendo.2021.769187
Morimont, Laure, et al. "Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk." Frontiers in endocrinology vol. 12 (2021): 769187. doi: https://doi.org/10.3389/fendo.2021.769187
Morimont L, Haguet H, Dogné JM, Gaspard U, Douxfils J. Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk. Front Endocrinol (Lausanne). 2021 Dec 09;12:769187. doi: 10.3389/fendo.2021.769187. eCollection 2021. PMID: 34956081; PMCID: PMC8697849.
Copy Download .nbib Format: NLM
Pharmacological profile of progestins.

Maturitas

Sitruk-Ware R.
PMID: 19434887
Maturitas. 2008 Sep-Oct;61(1):151-7. doi: 10.1016/j.maturitas.2008.11.011.

The synthetic progestins used so far for contraception and menopausal hormone therapy are derived either from testosterone (19-nortestosterone derivatives) or from progesterone (17-OH progesterone derivatives and 19-norprogesterone derivatives). Among the 19-nortestosterone derivatives, the estrane group include norethisterone (NET) and...

Cite
Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2008;61(1):151-7doi: 10.1016/j.maturitas.2008.11.011.
Sitruk-Ware, R. (2008). Pharmacological profile of progestins. Maturitas, 61(1), 151-7. https://doi.org/10.1016/j.maturitas.2008.11.011
Sitruk-Ware, Regine. "Pharmacological profile of progestins." Maturitas vol. 61,1 (2008): 151-7. doi: https://doi.org/10.1016/j.maturitas.2008.11.011
Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1):151-7. doi: 10.1016/j.maturitas.2008.11.011. PMID: 19434887.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 12949633
Methods Find Exp Clin Pharmacol. 2003 Jul-Aug;25(6):483-506.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies Knowledge Area of Prous Science Integrity, the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003;25(6):483-506
Bayés, M., Rabasseda, X., & Prous, J. R. (2003). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 25(6), 483-506.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 25,6 (2003): 483-506.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Jul-Aug;25(6):483-506. PMID: 12949633.
Copy Download .nbib Format: NLM
Effectiveness and acceptability of progestogens in combined oral contraceptives - a systematic review.

Reproductive health

Kulier R, Helmerhorst FM, Maitra N, Gülmezoglu AM.
PMID: 15357865
Reprod Health. 2004 Jun 03;1(1):1. doi: 10.1186/1742-4755-1-1.

BACKGROUND: The progestogen component of oral contraceptives (OCs) has undergone changes since it was recognized that their chemical structure can influence the spectrum of minor adverse and beneficial effects. METHODS: The objective of this review was to evaluate currently...

Cite
Kulier R, Helmerhorst FM, Maitra N, et al. Effectiveness and acceptability of progestogens in combined oral contraceptives - a systematic review. Reprod Health. 2004;1(1):1doi: 10.1186/1742-4755-1-1.
Kulier, R., Helmerhorst, F. M., Maitra, N., & Gülmezoglu, A. M. (2004). Effectiveness and acceptability of progestogens in combined oral contraceptives - a systematic review. Reproductive health, 1(1), 1. https://doi.org/10.1186/1742-4755-1-1
Kulier, Regina, et al. "Effectiveness and acceptability of progestogens in combined oral contraceptives - a systematic review." Reproductive health vol. 1,1 (2004): 1. doi: https://doi.org/10.1186/1742-4755-1-1
Kulier R, Helmerhorst FM, Maitra N, Gülmezoglu AM. Effectiveness and acceptability of progestogens in combined oral contraceptives - a systematic review. Reprod Health. 2004 Jun 03;1(1):1. doi: 10.1186/1742-4755-1-1. PMID: 15357865; PMCID: PMC483073.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 22 entries